CD8A and acute myeloid leukemia: In addition, we have previously shown that CD8+-specific LAA immune responses against Preferentially expressed Antigen in Melanoma (PRAME), WT-1, RHAMM, or NPM1mut expressing LPCs/LSCs from AML patients with mutated or wild-type NPM1 were similar except for their response to NPM1mut epitopes which were only seen in samples from NPM1mut patients (vide supra).